Altimmune, Inc.
Altimmune, Inc. (ALT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ALT · as of Jun 8, 2026
Key Statistics
Explore Altimmune, Inc. Data
alt stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 15 · Buy rate: 80.0%
The ALT analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month price target is $11.25, representing +315.13% upside from the current price of $2.71.
Competitors & Peers
alt competitorsALT
ACIU
AMRN
ANNX
ANRO
AURAStock Performance
Full HistoryAbout Altimmune, Inc.
Altimmune, Inc. a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly …
what is altimmune, inc. · alt stock overview · altimmune, inc. company profile · who is altimmune, inc. ceo · alt NASDAQ · altimmune, inc. headquarters · altimmune, inc. business segments
About Stock Overview & Key Data
Altimmune, Inc. (ALT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 26, 2017. As of the latest trading session, ALT stock price is $2.71, with a market capitalization of $239.2M. The stock has returned -54.45% over the past 12 months and -24.93% year-to-date.
According to 15 Wall Street analysts, the consensus rating for Altimmune, Inc. stock is Buy, with an average 12-month price target of $11.25. In fiscal year 2025, Altimmune, Inc. reported revenue of $41000.00 and net income of -$88.1M. For detailed data — including Altimmune, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Altimmune, Inc. (ALT) stock price is $2.71. The stock is traded on NASDAQ under the ticker symbol ALT. The 52-week range is $2.56 – $7.73.